Section Arrow
GLPG.NASDAQ
- Galapagos NV
Quotes are at least 15-min delayed:2025/07/25 14:59 EDT
Regular Hours
Last
 32.15
+1.3 (+4.21%)
Day High 
32.2 
Prev. Close
30.85 
1-M High
33.8563 
Volume 
261.62K 
Bid
32.11
Ask
32.16
Day Low
31.02 
Open
31.34 
1-M Low
27.54 
Market Cap 
2.03B 
Currency USD 
P/E 53.04 
%Yield -- 
10-SMA 31.22 
20-SMA 29.96 
50-SMA 28.91 
52-W High 33.8563 
52-W Low 22.36 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.58/1.86
Enterprise Value
2.04B
Balance Sheet
Book Value Per Share
48.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
275.65M
Operating Revenue Per Share
8.74
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0575+0.0035+6.48%-- 
ABPAbpro Holdings Inc0.3115+0.0454+17.06%-- 
TNFATNF Pharmaceuticals Inc.0.1166-0.0154-11.67%-- 
PHIOPhio Pharmaceuticals Corp3.18+0.67+26.69%0.01PE
ABSIAbsci Corp2.85-0.66-18.80%-- 
Quotes are at least 15-min delayed:2025/07/25 14:59 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, aBCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.